{"nctId":"NCT01089127","briefTitle":"Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2010-03"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":552,"armGroups":[{"label":"Indacaterol 18.75 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to salmeterol"]},{"label":"Indacaterol 37.5 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to salmeterol"]},{"label":"Indacaterol 75 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to salmeterol"]},{"label":"Indacaterol 150 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol","Drug: Placebo to salmeterol"]},{"label":"Salmeterol 50 μg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Salmeterol 50 μg","Drug: Placebo to indacaterol"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol","Drug: Placebo to salmeterol"]}],"interventions":[{"name":"Indacaterol","otherNames":[]},{"name":"Salmeterol 50 μg","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]},{"name":"Placebo to salmeterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease \\[GOLD\\] Guidelines, 2008) and:\n\n  1. Smoking history of at least 10 pack-years\n  2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value\n  3. Post-bronchodilator FEV1/FVC (forced vital capacity) \\< 70%\n\nExclusion criteria:\n\n* Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to screening\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular comorbid conditions\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 2 + 1 Day, Day 15)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.35","spread":"0.020"},{"groupId":"OG001","value":"1.38","spread":"0.019"},{"groupId":"OG002","value":"1.38","spread":"0.019"},{"groupId":"OG003","value":"1.40","spread":"0.019"},{"groupId":"OG004","value":"1.39","spread":"0.019"},{"groupId":"OG005","value":"1.28","spread":"0.019"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose on Day 2","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose on Day 2. The analysis included baseline FEV1, FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening, and FEV1 pre-dose and 1 hour post-dose of ipratropium during screening as covariates.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.33","spread":"0.015"},{"groupId":"OG001","value":"1.34","spread":"0.015"},{"groupId":"OG002","value":"1.38","spread":"0.015"},{"groupId":"OG003","value":"1.40","spread":"0.014"},{"groupId":"OG004","value":"1.41","spread":"0.015"},{"groupId":"OG005","value":"1.28","spread":"0.015"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":89},"commonTop":["Cough","Vomiting","Blood creatine phosphokinase increased","Headache","Dermatitis contact"]}}}